Evidence map›Paper›PMID 36298703›Full record

ArticleViruses2022

Dynamics of SARS-CoV-2 Variants of Concern in Vaccination Model City in the State of Sao Paulo, Brazil.

Svetoslav Nanev Slavov, Debora Glenda Lima de La-Roque, Pericles Natan Mendes da Costa, Evandra Strazza Rodrigues, Elaine Vieira Santos, Josiane Serrano Borges, Mariane Evaristo, Juliana de Matos Maçonetto, Adriana Aparecida Marques, Jonathan Milhomens and 20 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 1 country.

Svetoslav Nanev SlavovCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.ORCID 0000-0003-0805-6140
Debora Glenda Lima de La-RoqueCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Pericles Natan Mendes da CostaCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Evandra Strazza RodriguesCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.ORCID 0000-0003-0964-9554
Elaine Vieira SantosCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Josiane Serrano BorgesCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Mariane EvaristoCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Juliana de Matos MaçonettoCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Adriana Aparecida MarquesCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Jonathan MilhomensCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Felipe Augusto RósCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.ORCID 0000-0001-7058-998X
Vagner FonsecaPan-American Health Organization/World Health Organization, Lote 19-Avenida das Nações, SEN-Asa Norte, Brasília 70312-970, Brazil.ORCID 0000-0001-5521-6448
Alex Ranieri Jerônimo LimaButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
Gabriela RibeiroButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
Loyze Paola Oliveira de LimaButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
Pedro Manuel Marques GaribaldiSerrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil.
Natasha Nicos FerreiraSerrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil.
Glenda Renata MoraesHealth Department, Tancredo Almeida Neves Street, 176, Serrana 14150-000, Brazil.
Elaine Cristina MarquezeButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.ORCID 0000-0002-4987-7757
Claudia Renata Dos Santos BarrosButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.ORCID 0000-0002-1582-2010
Antonio Jorge MartinsButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
Luiz Lehmann CoutinhoCollege of Agriculture "Luiz de Queiroz", University of São Paulo, Pádua Dias Street, 235, Piracicaba 13418-900, Brazil.
Rodrigo Tocantins CaladoCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Marcos BorgesSerrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil.
Maria Carolina EliasButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.ORCID 0000-0002-0501-8280
Sandra Coccuzzo SampaioButantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil.
Marta GiovanettiOswaldo Cruz Foundation, Rio de Janeiro 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-5849-7326
Luiz Carlos Junior AlcantaraOswaldo Cruz Foundation, Rio de Janeiro 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil.
Dimas Tadeu CovasCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Simone KashimaCenter for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Instituto Butantan · BRUniversidade de São Paulo · BRFundação Oswaldo Cruz · BRPan American Health Organization (Brasil) · BR

Funding

University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
NIAID NIH HHS U01 AI151698World Health Organization 001
6 · The paper itself

Abstract

From a country with one of the highest SARS-CoV-2 morbidity and mortality rates, Brazil has implemented one of the most successful vaccination programs. Brazil's first model city vaccination program was performed by the CoronaVac vaccine (Sinovac Biotech) in the town of Serrana, São Paulo State. To evaluate the vaccination effect on the SARS-CoV-2 molecular dynamics and clinical outcomes, we performed SARS-CoV-2 molecular surveillance on 4375 complete genomes obtained between June 2020 and April 2022 in this location. This study included the period between the initial SARS-CoV-2 introduction and during the vaccination process. We observed that the SARS-CoV-2 substitution dynamics in Serrana followed the viral molecular epidemiology in Brazil, including the initial identification of the ancestral lineages (B.1.1.28 and B.1.1.33) and epidemic waves of variants of concern (VOC) including the Gamma, Delta, and, more recently, Omicron. Most probably, as a result of the immunization campaign, the mortality during the Gamma and Delta VOC was significantly reduced compared to the rest of Brazil, which was also related to lower morbidity. Our phylogenetic analysis revealed the evolutionary history of the SARS-CoV-2 in this location and showed that multiple introduction events have occurred over time. The evaluation of the COVID-19 clinical outcome revealed that most cases were mild (88.9%, 98.1%, 99.1% to Gamma, Delta, and Omicron, respectively) regardless of the infecting VOC. In conclusion, we observed that vaccination was responsible for reducing the death toll rate and related COVID-19 morbidity, especially during the gamma and Delta VOC; however, it does not prevent the rapid substitution rate and morbidity of the Omicron VOC.

Indexed as

COVID-19SARS-CoV-2BrazilHumansPhylogenyVaccinationCOVID-19 vaccinesDeltaGammaOmicronSARS-CoV-2 variantsvariants of concern (VOC)

Identifiers

PMID36298703
PMCPMC9609010
OpenAlexW4298145326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.